What sector does Akums Drugs And Pharma L belong to?

Akums Drugs And Pharma L operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of AKUMS?

As of the latest available quote, AKUMS traded at ₹776.35. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of AKUMS?

Akums Drugs And Pharma L has a price-to-earnings (P/E) ratio of about 40.82. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of AKUMS?

The market capitalisation of Akums Drugs And Pharma L is approximately ₹12,219 Cr.

Is Akums Drugs And Pharma L profitable?

For its latest reported financial year, Akums Drugs And Pharma L recorded a net profit margin of about 5.87%.

Does AKUMS pay a dividend?

Akums Drugs And Pharma L does not currently show a dividend yield in our data.

What is the return on equity (ROE) of AKUMS?

Akums Drugs And Pharma L has a return on equity (ROE) of about 8.45%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of AKUMS?

Over the past 52 weeks, AKUMS has traded between a low of ₹409.30 and a high of ₹796.55.

Akums Drugs And Pharma L

AKUMS NSE Healthcare Pharmaceuticals

Microcap 250

₹776.35

+3.56%

Delayed · cached 15 min

Fair value analysis

AKUMS

Akums Drugs And Pharma L

₹749.65

Close used for this calculation

₹749.33Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

52/100

Profitability19/25

Returns4/25

Balance Sheet21/25

Efficiency8/25

Growth14/25

Good

Quality radar

Consensus fair value

₹749.33

Near FV

▼ 0.0% against the close used

Model range ₹149.56 – ₹1,166.61

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹149.56Fair value₹749.33Bull₹1,166.61

FairClose

52-week traded range

52W low ₹414.0552W high ₹780.55

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Akums Drugs And Pharma L closed at ₹749.65, 0.0% above the consensus fair value of ₹749.33 drawn from 9 valuation models.

Financial DNA score 52/100 — Good. P/E of 40.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹1,166.61

+55.6%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹298.43

-60.2%

√(22.5 × EPS × BVPS)

EPS=16.21, BVPS=244.19 · outside Graham range (P/E 40, P/B 3.1) — asset-light, treat as a rough floor

Graham Formula

₹730.03

-2.6%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=20%, FD=7%

P/E Fair Value

₹578.70

-22.8%

EPS × 35.7x (sector P/E)

EPS=16.21, Sector P/E=35.7x

Peter Lynch (PEG)

₹405.25

-45.9%

EPS × Growth% (PEG = 1 is fair)

EPS=16.21, g=25%

EV/EBITDA

₹737.99

-1.6%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=6.77B

Book Value (P/B)

₹149.56

-80.0%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=244.19, ROE=8.5%, g=6%, r=10%

Reverse DCF

₹749.65

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 18.5% | Historical: 25%

Margin of Safety

₹520.08

-30.6%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=693.44, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer